EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

Ítems similars

• Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis
  per: Ronald SA de Vreeze, et al.
  Publicat: (2008)
• Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?: A Molecular Biological Analysis
  per: de Vreeze, Ronald, et al.
  Publicat: (2010)
• Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience
  per: de Vreeze, Ronald S. A., et al.
  Publicat: (2009)
• Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
  per: Hummelink, Karlijn, et al.
  Publicat: (2019)
• Prognostic Significance of ^99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung Cancer
  per: Marina Kartachova, et al.
  Publicat: (2007)